Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 328 clinical trials
None
Monitoring the IgG/IgM Antibodies in COVID-19 Patients

repurposed and employed, but no specific antiviral medicine has been approved by the FDA to treat this disease. Although three vaccines have been approved by the FDA, mutations in the SARS-CoV-2 may cause

  • 0 views
  • 16 Jul, 2021
  • 2 locations
None
Predictive Immune Biomarkers of COVID-19 Pathogenesis to Influence Therapeutic Management

deterioration often coincides with the development of host antiviral immune responses. The inflammatory response to SARS-CoV-2 infection may underpin COVID-19 pathogenesis leading to aberrant and excessive

  • 0 views
  • 26 Jan, 2021
  • 2 locations
None
Quantification of Binding and Neutralizing Antibody Levels in COVID-19 Vaccinated Health Care Workers Over 1 Year

treat a wide range of symptoms including the use of the antiviral drug remdesivir, convalescent plasma, antibiotics, steroids, and anticoagulant therapy. To prevent the spread of the disease, multiple

antibiotics
SARS
  • 0 views
  • 13 Jun, 2021
  • 1 location
None
Mechanism of DCs Dysfunction in Chronic HBV Infection

This research is to better understand the functional impairments of Dendritic cells (DCs) in chronic HBV infection. Aim is to determine if the virus is able to bind to the C-type lectin receptor (CLRs) of DCs to modulate their functions, also, to define the role of viral components and the …

antiviral agents
steatosis
hepatitis b antigen
antiviral
metabolic syndrome
  • 16 views
  • 26 Jan, 2021
  • 1 location
None
Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites

This study will evaluate the intracellular pharmacokinetics and platelet effects of abacavir (ABC), lamivudine (3TC), tenofovir alafenamide (TAF), and emtricitabine (FTC) in persons living with HIV that are receiving these medications as part of standard HIV care. Participants remaining on ABC/3TC- or TAF/FTC-containing therapy will be on study for 4 …

  • 0 views
  • 06 Oct, 2021
  • 1 location
None
The Hepatitis C Transplant Collaborative

In this study we seek to test the hypothesis that safety and clinical outcomes after cardiac transplantation utilizing HCV NAT+ donor organs as currently performed are acceptable.

  • 3 views
  • 26 Jan, 2021
  • 1 location
None
Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons

Background COVID-19 virus infection differs among people. Some people have no or mild symptoms. For others, COVID-19 is life threatening and causes damage to the body s organs. Researchers want to better understand the virus to learn how to kill it. Objective To understand how the COVID-19 virus causes wide …

  • 0 views
  • 12 Aug, 2021
  • 2 locations
None
Immune Response in Patients With Hepatitis B and C Infection

Using peripheral blood mononuclear cells (PBMC) and serum collection from HBV and HCV infected patients in a number of different immunological assays, the investigators hope to identify any changes in the number and function of these immune cells and to investigate how these changes contribute to viral persistence and disease …

hepatitis
antiviral agents
antiviral drugs
hepatitis b
chronic hepatitis
  • 341 views
  • 27 Jan, 2021
  • 2 locations
None
Long-term Outcomes of Chronic Hepatitis C Patients Post Sofosbuvir-based Treatment

Primary Objective: To evaluate the long-term outcomes including liver related morbidity, mortality and hepatocellular carcinoma (HCC) development as compared to those of historical control with interferon(IFN)-based treatment. Secondary Objective: To access liver fibrosis progression/regression in CHC patients after sofosbuvir-based treatment. To investigate the long-term outcomes of extrahepatic manifestations of the …

fibrosis
carcinoma
hepatitis
ribavirin
hepatocellular carcinoma
  • 40 views
  • 22 Oct, 2021
  • 19 locations
None
HCV Reinfection in HD Patients Achieving SVR

Among the hemodialysis units, the global incidence of HCV infection ranges from 1.2% to 2.9%. Data regarding the long-term risk of reinfection among hemodialysis patients achieving SVR are limited. To our best knowledge, only one study assessed the long-term negativity of serum HCV RNA in hemodialysis patients who achieved SVR …

  • 0 views
  • 06 Mar, 2021
  • 7 locations